{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"27.9","upperLimit":"27.9","value":"27.9"},{"groupId":"OG001","lowerLimit":"28.8","upperLimit":"49.5","value":"39.2"},{"groupId":"OG002","lowerLimit":"13.4","upperLimit":"24.5","value":"20.8"},{"groupId":"OG003","lowerLimit":"16.7","upperLimit":"16.8","value":"16.8"},{"groupId":"OG004","lowerLimit":"14.9","upperLimit":"19.6","value":"15.2"},{"groupId":"OG005","lowerLimit":"12.0","upperLimit":"18.7","value":"14.0"},{"groupId":"OG006","lowerLimit":"16.1","upperLimit":"18.9","value":"17.6"},{"groupId":"OG007","lowerLimit":"11.8","upperLimit":"14.5","value":"13.2"},{"groupId":"OG008","lowerLimit":"13.3","upperLimit":"19.1","value":"16.2"},{"groupId":"OG009","lowerLimit":"11.6","upperLimit":"41.1","value":"17.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"7"},{"groupId":"OG007","value":"2"},{"groupId":"OG008","value":"2"},{"groupId":"OG009","value":"9"}],"units":"Participants"}],"description":"T1/2 is the Elimination half-life.","dispersionType":"Full Range","groups":[{"description":"Participants received 45 mg LTT462 QD as oral capsules.","id":"OG000","title":"LTT462 45 mg QD"},{"description":"Participants received 100 mg LTT462 QD as oral capsules.","id":"OG001","title":"LTT462 100 mg QD"},{"description":"Participants received 150 mg LTT462 QD as oral capsules.","id":"OG002","title":"LTT462 150 mg QD"},{"description":"Participants received 200 mg LTT462 QD as oral capsules.","id":"OG003","title":"LTT462 200 mg QD"},{"description":"Participants received 300 mg LTT462 QD as oral capsules.","id":"OG004","title":"LTT462 300 mg QD"},{"description":"Participants received 400 mg LTT462 QD as oral capsules.","id":"OG005","title":"LTT462 400 mg QD"},{"description":"Participants received 450 mg LTT462 QD as oral capsules.","id":"OG006","title":"LTT462 450 mg QD"},{"description":"Participants received 600 mg LTT462 QD as oral capsules.","id":"OG007","title":"LTT462 600 mg QD"},{"description":"Participants received 150 mg LTT462 twice daily (BID) as oral capsules.","id":"OG008","title":"LTT462 150 mg BID"},{"description":"Participants received 200 mg LTT462 BID as oral capsules.","id":"OG009","title":"LTT462 200 mg BID"}],"paramType":"MEDIAN","populationDescription":"PAS included of all participants who have at least 1 PK blood sample providing measurable LTT462 and received at least 1 dose of study drug, didn't vomit within 4 hours postdose, had at least 1 primary PK parameter. Here 'N' number of participants analyzed signifies number of participants who were evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Days 1, 2, 3, 8, 15 and 16; Cycle 2 day 1 and 15; Cycle 3 Day 1; Cycle 5 Day 1","title":"Elimination Half-life (T1/2) of LTT462","type":"SECONDARY","unitOfMeasure":"hour"}